“Adaptive Licensing” Proposals View REMS As Answer To Limited Evidence
Some ideas for new drug approval pathways seem to envision the use of Risk Evaluation and Mitigation Strategies as a means for preventing and monitoring off-label use following initial approval, apparently without regard to the seriousness or extent of a product’s risks. Given the burdens currently created by REMS, any effort to expand and retrofit the programs to a new approval pathway is likely to draw pushback from the health care community.
You may also be interested in...
Adaptive licensing is coming to Europe and, while it will be beneficial to patients, data exclusivity considerations may render it a double-edged sword to the innovative drug industry.
With Singapore’s biomedical infrastructure and small population, it is an ideal place to test devices that could redefine the way therapies are developed and monitored.
The Executive Director of the European Medicines Agency Guido Rasi’s dual goals of increasing safety and overall accountability undoubtedly will benefit patients and industry alike, but a grueling task lies ahead.